Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
about
Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.Long-term treatment of epilepsy with everolimus in tuberous sclerosis.Dysplasia and overgrowth: magnetic resonance imaging of pediatric brain abnormalities secondary to alterations in the mechanistic target of rapamycin pathway.Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.Harnessing the mTOR Pathway for Tuberculosis Treatment.Rapid regression of large cardiac rhabdomyomas in neonates after sirolimus therapy.Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma.Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.Coexistence of SLE, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated?Tuberous sclerosis complex: review based on new diagnostic criteria.Expanding the Clinical Spectrum of Sotos Syndrome in a Patient with the New "c.[5867T>A]+[=]"; "p.[Leu1956Gln]+[=]" Missense Mutation and Complex Skin HamartomaA rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells
P2860
Q37597272-BCE9B2D2-B1A4-49CB-9859-182F83E5F420Q37697798-CA7EBECC-ADBA-4787-B8CC-CF8C4473B8E7Q37721031-FC4D8AAB-B460-4C87-8AAC-D64D14A6B864Q46836536-769D7A09-DA86-4881-8F36-C3B71188A611Q47894572-7C7E9A31-9684-41B2-93E7-2D77AF119B3FQ48297402-CE22DDA2-8676-43D7-8901-37C6407DE86AQ49417693-F4A5328E-EE5C-4A06-A09D-1F24A48D5543Q49890771-C359F6FE-B838-43AA-A89E-6EA56BC3A8A0Q53139594-8ED33FAE-2E8A-4423-844C-F8D1583A73B6Q53828437-D2C9C893-DF8F-4196-B8B6-29D39234C8E5Q54518611-E4A0C315-CBE2-4A99-8067-53C72706A496Q55277251-C7933AD5-0DD4-4CDA-88C8-F4C216C55AB3Q58555740-B708551D-424F-41E1-BAFE-731442CAC2D1Q58589497-4A807DA3-B183-44E9-9D5C-B8F85AB0883B
P2860
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@ast
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@en
type
label
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@ast
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@en
prefLabel
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@ast
Differentiating the mTOR inhib ...... of tuberous sclerosis complex.
@en
P2860
P356
P1433
P1476
Differentiating the mTOR inhib ...... of tuberous sclerosis complex
@en
P2093
Darcy A Krueger
P2860
P304
P356
10.1093/NEUONC/NOV152
P577
2015-08-19T00:00:00Z